Placulumab

Placulumab (ART621) is an anti-TNF α monoclonal antibody. Placulumab has anti-inflammatory activity and has potential applications in inflammatory diseases such as arthritis[1].

Research Areas >> Inflammation/Immunology

Placulumab (0.01-1000 µg/mL) 对 NS0 细胞和外周血单个核细胞 (PBMC) 具有细胞毒性[1]。

Placulumab (0.3、1、3 和 10 mg/kg；腹腔注射；每周两次持续 8 周) 在 Tg197 转基因小鼠模型中具有有效的抗关节炎特性[1]。 Placulumab 在食蟹猴中的药代动力学 (PK) 参数[1] Route Dose (mg/kg) Exposure AUC0-336 h (ng.h/mL) Maximum concentration Cmax (ng/mL) Time of maximum concentration tmax (h) Elimination half-life t1/2 (h) Clearance CL (mL/hr/kg) Intravenous injection (Males) 50 46000000 1320000 0.167 104 0.985 Intravenous injection (Females) 50 43300000 1020000 0.211 97.4 1.06 Route Dose (mg/kg) Exposure AUC0-336 h (ng.h/mL) Dose normalize exposure AUC0-336 h (norm) Maximum concentration Cmax (ng/mL) Time of maximum concentration tmax (h) Elimination half-life t1/2 (h) Subcutaneous injection (Males) 0.5 676000 1350000 3190 50.0 120 Subcutaneous injection (Females) 0.5 445000 890000 2880 48.0 108 Subcutaneous injection (Males) 5 3940000 788000 22700 40.0 117 Subcutaneous injection (Females) 5 3840000 767000 23800 12.0 109 Subcutaneous injection (Males) 50 41600000 832000 272000 40.0 122 Subcutaneous injection (Females) 50 32300000 646000 212000 32.0 107

[1]. Gay RD, et al. Anti-TNFα domain antibody construct CEP-37247: Full antibody functionality at half the size. MAbs. 2010 Nov-Dec;2(6):625-38.